United States

Pfizer Animal Health Introduces INFORCE™ 3 Respiratory Vaccine

Vaccine demonstrated to prevent BRSV and aid in the prevention of IBR and PI3

NEW YORK — Aug. 23, 2010 — INFORCE™ 3, a new three-way respiratory cattle vaccine, will be available Sept. 1 from Pfizer Animal Health. The intranasal vaccine offers unprecedented respiratory protection with the highest level of disease prevention available against bovine respiratory syncytial virus (BRSV). INFORCE 3 also is labeled to aid in the prevention of infectious bovine rhinotracheitis (IBR) and parainfluenza type 3 (PI3).

In Pfizer Animal Health efficacy studies, all calves vaccinated with INFORCE 3 survived a severe BRSV challenge in which 95 percent of unvaccinated controls died.1,2 The studies also demonstrated that those calves vaccinated with INFORCE 3 showed fewer lung lesions and reduced viral shedding, indicating vaccinated calves are less likely to suffer from chronic BRSV disease and to transmit disease. Additionally, INFORCE 3 was shown to help prevent respiratory disease caused by IBR and PI3, and reduce IBR and PI3 viral shedding.3,4,5

“It is important to help get dairy and beef calves off to a healthy start and bolster their immune systems early to fight against costly and deadly respiratory diseases,” says Victor Cortese, DVM, PhD, Dipl. ABVP, director, Veterinary  Specialties Group, Pfizer Animal Health. “BRSV is a major cause of viral pneumonia in young cattle.6 INFORCE™ 3 has demonstrated unmatched efficacy against BRSV. It is approved for use in cattle of all ages, so it also fits vaccination protocols for incoming stocker and feedlot cattle, and transition dairy cattle.”  

INFORCE 3 helps provide protection in a 2 mL intranasal dose, with I mL given in each nostril.* 

“INFORCE 3 helps prime the immune system for a strong memory response to subsequent vaccinations, as well as respiratory disease challenges, helping offer calves a stronger, healthier start,” Dr. Cortese says. 

INFORCE 3 contains proprietary, temperature-sensitive IBR and PI3 strains, as well as naturally temperature-sensitive BRSV. This means that the vaccine strains grow only in the relatively cool nasal passages.

In addition to unmatched efficacy and demonstrated safety, INFORCE 3 comes in a new user-friendly package design. Multilingual icons developed specifically for the package allow for quick visual identification of approved uses and handling instructions. The package also offers a tear-off, pressure-sensitive label that includes lot information to assist in inventory control and record-keeping.

“For the best chance of achieving a successful immunization, vaccines must be properly administered and handled,” adds Dr. Cortese. “We recognize the need for clearer, more understandable vaccination packaging to help producers and employees utilize our products appropriately.” 

INFORCE 3 is available in four vial sizes: 1-dose, 10-dose, 25-dose and 50-dose. It is safe for beef and dairy cattle of all ages, including pregnant females and newborn calves.

For more information, producers should talk with their veterinarian or Pfizer Animal Health representative, or call 800-733-5500.

Pfizer Animal Health, a business of Pfizer Inc., is a world leader in discovering and developing innovative animal vaccines and prescription medicines, investing an estimated $300 million annually in animal health product research and development. For more information about how Pfizer Animal Health works to ensure a safe, sustainable global food supply from healthy livestock and poultry; or helps companion animals and horses to live longer, healthier lives, visit www.PfizerAH.com.

* Calves vaccinated prior to 6 months of age should be revaccinated after six months. 
1 Data on file, Study Report No. 3131R-60-08-557, Pfizer Inc.
2 Data on file, Study Report No. 3131R-60-09-669, Pfizer Inc.
3 Data on file, Study Report No. 3131R-60-08-548, Pfizer Inc.
4 Data on file, Study Report No. 3131R-60-09-720, Pfizer Inc. 
5 Data on file, Study Report No. 3131R-60-08-568, Pfizer Inc. 
6 Steven T, Grubbs ST, Kania SA, Potgieter LND. Prevalence of ovine and bovine respiratory syncytial virus infection in cattle determined with a synthetic peptide-based immunoassay. J Vet Diagn Invest 2001;13:128-132

All brands are the property of Pfizer Inc., its affiliates and/or its licensors. ©2010 Pfizer Inc. All rights reserved. INF10011 

FOR IMMEDIATE RELEASE
Laura Pires
Pfizer Animal Health
(212) 733-1102
laura.pires@pfizer.com

Michelle Tollefson
Pfizer Animal Health
(212) 733-0502
michelle.tollefson@pfizer.com

Laurie Peterson
Bader Rutter & Associates
(262) 938-5419
lpeterson@bader-rutter.com